Cingulate Inc. Announces Key Stockholder Approvals and Sales Agreement

Summary of Key Developments

• Approval of Issuance of Common Stock upon Preferred Conversion & Warrants Exercise: Shareholders approved the issuance of common stock upon conversion of Series A Convertible Preferred Stock and/or on the exercise of warrants, both issued under a recent securities purchase agreement.
• Sales Agreement for “At-the-Market” Offerings: Cingulate Inc. entered into a Sales Agreement with A.G.P./Alliance Global Partners to sell shares from time to time, directly into the market, under an effective shelf registration statement.

Details from the Special Meeting of Stockholders

On March 24, 2026, Cingulate Inc. held a Special Meeting of Stockholders where two major proposals were presented:

Proposal 1: Approval of Stock Issuances (Nasdaq Rule 5635(b) Compliance)

• Shareholders approved, for purposes of complying with Nasdaq Listing Rule 5635(b), the issuance of common stock upon conversion of Series A Convertible Preferred Stock and/or the exercise of warrants issued as part of the January 27, 2026 securities purchase agreement.
• This approval allows Cingulate to potentially increase its common stock outstanding, which could impact the share price depending on conversion and warrant exercise activity.

Proposal 2: Adjournment Option

• Shareholders also approved the adjournment of the Special Meeting, if necessary, to solicit further votes for Proposal 1. However, adjournment was not needed since Proposal 1 passed with sufficient support.

Sales Agreement for At-the-Market (ATM) Offerings

Cingulate Inc. entered into a Sales Agreement with A.G.P./Alliance Global Partners (the “Sales Agent”), allowing for the sale of its common stock (par value \$0.0001 per share) directly into the market from time to time, as an at-the-market (ATM) offering.

• The shares are registered under a shelf registration statement (Form S-3, File No. 333-292680) with an effective base prospectus and supplements, complying with SEC regulations.
• Shares sold under this agreement will be fully paid, non-assessable, issued in compliance with all applicable securities laws, and free of preemptive or similar rights.
• No person has registration or similar rights that could force inclusion of their securities in this ATM offering.
• The company affirms that it is not aware of any material adverse change in its business or finances since the latest SEC filings, nor any undisclosed legal proceedings or regulatory issues.
• The company is in compliance with Sarbanes-Oxley, Nasdaq, and SEC rules, and its financial statements have been audited by KPMG LLP.
• The net proceeds from any sales will be used as described in the prospectus supplement under “Use of Proceeds”.
• The company is required to keep the registration statement effective, file timely reports, and promptly disclose any material events or changes in circumstances that could affect investors.

Potential Shareholder Impact and Price Sensitivity

• Dilution Risk: The approvals allow the company to issue additional common shares upon conversion of preferred stock and exercise of warrants, which could dilute existing shareholders. Any significant issuance or conversion may impact the market price.
• ATM Sales: The company can now raise funds opportunistically by selling shares directly into the market, potentially at prevailing prices. Such sales can support company operations but may also put downward pressure on the share price depending on volume and market conditions.
• No Known Material Adverse Change: Management affirms there has been no material adverse change since the last filings, a positive signal for investors.
• Regulatory and Legal Compliance: Ongoing compliance with Sarbanes-Oxley, Nasdaq, and other regulations is affirmed, and there are no undisclosed material legal issues.

Other Notable Details

• The company will maintain a registrar and transfer agent for the common stock at its own expense.
• Insurance coverage is in place and considered adequate for ongoing business operations.
• The company is not a party to any other “at the market” or continuous equity transaction agreements.
• There are no undisclosed related party transactions, and all required disclosures have been made.
• The Sales Agent, A.G.P./Alliance Global Partners, will be compensated according to the terms set forth, and the company will bear related costs, including legal and regulatory compliance fees.

Conclusion

The approval of additional share issuances and the execution of the ATM Sales Agreement are both significant corporate actions. They provide Cingulate with enhanced financial flexibility but also introduce potential dilution risks for current shareholders. Investors should closely monitor future filings for updates on actual share sales, conversions, and warrant exercises, as these could impact the market price and company valuation.

Disclaimer: This article is provided for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial professionals before making investment decisions. Past performance is not indicative of future results. The author and publisher assume no liability for any actions taken based on the information provided herein.

View Cingulate Inc. Historical chart here